Informationen:
Fehler:
ID
34524
Beschreibung
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE); ODM derived from: https://clinicaltrials.gov/show/NCT01384461
Link
https://clinicaltrials.gov/show/NCT01384461
Stichworte
Versionen (1)
- 18.01.19 18.01.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
18. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Rheumatoid Arthritis NCT01384461
Eligibility Rheumatoid Arthritis NCT01384461
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Rheumatoid Arthritis NCT01384461
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Adult | Age
Item
adult patients, >/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Rheumatoid arthritis disease activity, moderate | Rheumatoid Arthritis Severe
Item
moderate to severe rheumatoid arthritis
boolean
C2368567 (UMLS CUI [1])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
RoActemra | Actemra
Item
roactemra/actemra treatment initiated by rheumatologist in an arthritis center for (up to 2 months prior to study entry)
boolean
C3272237 (UMLS CUI [1])
C2740854 (UMLS CUI [2])
C2740854 (UMLS CUI [2])
Allergic Reaction Severe Investigational New Drug Component | Anaphylaxis Severe Investigational New Drug Component | Hypersensitivity Investigational New Drug Component
Item
history of severe allergic or anaphylactic reactions or known hypersensitivity to any component of the drug
boolean
C1527304 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C1705248 (UMLS CUI [2,4])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
C0205082 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C1705248 (UMLS CUI [2,4])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
Communicable Disease Severe | Recurrent infection
Item
active, severe infection or history of recurrent clinically significant infection
boolean
C0009450 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0239998 (UMLS CUI [2])
C0205082 (UMLS CUI [1,2])
C0239998 (UMLS CUI [2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Investigational New Drug
Item
treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before baseline visit
boolean
C0013230 (UMLS CUI [1])
Intolerance to Methotrexate
Item
methotrexate intolerance
boolean
C1744706 (UMLS CUI [1,1])
C0025677 (UMLS CUI [1,2])
C0025677 (UMLS CUI [1,2])